Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
AssigneeIdera Pharmaceuticals, Inc.
InventorsEkambar R. Kandimalla, Daqing Wang, Ireneusz Nowak, Sudhir Agrawal
Life of this patent
Estimating the term…
Abstract
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
Claims8
A method for therapeutically treating a mammal having inflammatory bowel disease or ulcerative colitis where inhibiting a TLR7- and/or TLR9-mediated immune response would be beneficial, such method comprising administering to the mammal an antagonist of TLR7 and/or TLR9 having the structure
- 5′-NpN3N2N1C*G1N1N2N3NzN4N5-3′ (SEQ ID NO:
- 72),
- wherein
- C*G* is an oligonucleotide motif wherein C* is 5-Me-dC, and G1 is 7-deaza-dG;
- N1-N2, at each occurrence, is independently a 2′-O-Me-ribonucleotide;
- N3, at each occurrence, is independently a nucleotide;
- N1-N3, at each occurrence, is independently a nucleotide;
- Nm and Nm, at each occurrence, is independently a nucleotide;
- N4-N5, at each occurrence, is independently a 2′-O-Me-ribonucleotide;
- p is 5;
- and
- z is 3;
- provided that the compound contains less than 3 consecutive guanosines.
Dependencies are inferred from the claim text.